

**NCBOP Compounding Summit Agenda**  
**February 24-26, 2026**  
**Friday Conference Center, Chapel Hill, NC**

**Tuesday, February 24, 2026: Registration and Welcome Reception**

- 3:00pm - 5:00pm** Registration Open at Courtyard Marriott Chapel Hill  
**5:00pm - 7:00pm** Welcome Reception at the Friday Conference Center

**Wednesday, February 25, 2026: Day 1 at Friday Center, Chapel Hill**

- 7:30am - 8:30am** Light Breakfast Provided (Friday Center Atrium)
- 8:30am - 8:45am** Opening Remarks
- 8:45am - 10:15am** 503B Outsourcing Facilities: What Are They & How Do They Prepare for an FDA Inspection?  
Traci Collier, PharmD, Director of Regulatory Affairs,  
Jessica McAlister, Director of Compliance,  
Olympia Pharmaceuticals
- 10:15am - 10:30am** Morning Refreshment Break (Friday Center Atrium)
- 10:30am - 11:30am** FDA Insanitary Conditions  
Matt Martin PharmD, BCSCP  
Vice President of Clinical Services, PCCA
- 11:30am - 12:00pm** Q&A Session with Speakers
- 12:00pm - 1:00pm** Lunch: Meal Provided
- 1:00pm - 2:30pm** Sterility Assurance: USP <71> and Alternative Testing Methods  
Michel van Musschenbroek, North American Marketing Manager,  
MilliporeSigma

**NCBOP Compounding Summit Agenda**  
**February 24-26, 2026**  
**Friday Conference Center, Chapel Hill, NC**

- 2:30pm - 2:45pm** Break: Refreshments Provided
- 2:45pm - 3:45pm** Compounding for Pediatrics  
Lisa Ashworth BS Pharm, BCSCP, FACA
- 3:45pm - 4:45pm** Medical Surveillance for Hazardous Drug Compounding  
Amy Snow MHS, CIH, CSP  
Managing Industrial Hygienist, Safe Bridge
- 4:45pm-5:00pm** Q&A Session with Speakers
- 5:00pm** Closing Remarks

**Thursday, February 26, 2026: Day 2 at Friday Center, Chapel Hill**

- 7:30am - 8:30am** Light Breakfast Provided (Friday Center Atrium)
- 8:30am - 8:45am** Opening Remarks
- 8:45am - 10:15am** Establishing Beyond Use Dates and Testing for Investigations  
Ross Caputo, PhD, President & CEO  
Eagle Analytical
- 10:15am - 10:30am** Break: Refreshments Provided
- 10:30am - 11:30 am** GLP-1 and Peptide Compounding: The Dark Side?  
Investigative Case Studies  
Jenni Wai, RPh, MBA, Chief Pharmacist  
Ohio Board of Pharmacy
- 11:30am - 12:00pm** Q&A Session with Speakers
- 12:00pm - 1:00pm** Lunch: Meal Provided
- 1:00pm - 2:30pm** Creating Effective CAPAs: From Root Cause to Communication Excellence  
Christine Hong, Lead Microbiologist
- 2:30pm -2:45pm** Break: Refreshments Provided

# **NCBOP Compounding Summit Agenda**

## **February 24-26, 2026**

### **Friday Conference Center, Chapel Hill, NC**

**2:45pm - 3:45pm** What Does Your Report Mean? Deep Dive into Certification Reports  
Kyle Mulder, Training and Technical Director  
Vanir Technology Group


**3:45pm - 4:15pm** Q&A With Speakers

**4:15pm** Closing Remarks

The continuing pharmacy education (CPE) activities presented during the Compounding Summit are designed to meet the educational needs of pharmacists and pharmacy technicians. Participants may earn up to 11 contact hours (1.1 CEU) of Accreditation Council for Pharmacy Education (ACPE)-accredited CPE credit. Additional details, including learning objectives for each CPE activity, system requirements for virtual attendees, and requirements for claiming CPE credit, will be available in the final CPE activity announcement.



The National Association of Boards of Pharmacy® (NABP®) and the NABP Foundation® are accredited by ACPE as providers of CPE. ACPE Provider Number: 0205



**NCBOP Compounding Summit**  
**February 24-26, 2026**  
**Friday Conference Center, Chapel Hill, NC**  
**CPE Program Details**

**Wednesday, February 25, 2026: Day 1 at Friday Center, Chapel Hill**

**8:45am - 10:15am 503B Outsourcing Facilities: What Are They & How Do They Prepare for an FDA Inspection?**

ACPE UANs: 0205-9999-26-013-L07-P/T  
(0.15 CEU – 1.5 contact hours)

After this knowledge-based activity, participants will be able to:

1. Discuss the differences between the regulatory frameworks governing 503A compounding pharmacies and 503B outsourcing facilities.
2. Review the operational scope and limitations of 503A versus 503B facilities.
3. Describe the Regulatory Requirements and Compliance Standards for 503B Outsourcing Facilities.
4. Express the ability to prepare documentation and records that meet FDA inspection standards.
5. Recognize effective audit readiness practices, including staff training, mock audits, and response protocols.

Speakers:

Traci Collier, PharmD, Director of Regulatory Affairs, Olympia Pharmaceuticals;  
Jessica McAlister, Director of Compliance, Olympia Pharmaceuticals

**10:30 am - 11:30 am FDA Insanitary Conditions**

ACPE UANs: 0205-9999-26-014-L07-P/T  
(0.1CEU – 1 contact hours)

After this knowledge-based activity, participants will be able to:

1. Recognize the requirements listed in FDA guidance documents for compounding compliance.
2. Identify the differences between FDA and USP requirements.
3. Explain how compounding practices are able to maintain compliance with both the FDA and USP standards.

Speaker:

Matt Martin, PharmD, BCSCP, Vice President of Clinical Services, PCCA

# NCBOP Compounding Summit

February 24-26, 2026

Friday Conference Center, Chapel Hill, NC

## CPE Program Details

**1:00 pm - 2:30 pm Sterility Assurance: USP <71> and Alternative Testing Methods**

ACPE UANs: 0205-9999-26-015-L07-P/T

(0.15CEU – 1.5 contact hour)

After this knowledge-based activity, participants will be able to:

1. Discuss the overview of USP Chapters <71> and <73>.
2. Describe Sterility Assurance and detection of contamination.
3. Review Rapid Sterility Methods currently being used.

Speaker:

Michel van Musschenbroek, MilliporeSigma

**2:45pm - 3:45pm Compounding for Pediatric Patients**

ACPE UANs: 0205-9999-26-016-L07-P/T

(0.1 CEU – 1 contact hour)

After this knowledge-based activity, participants will be able to:

1. Identify the age(s) of pediatric patients
2. Describe dosage forms used in pediatric patients and the need for compounding in this patient population
3. Review the USP standards for compounding and repackaging medications
4. Identify quality assurance practices to perform on compounded preparations

Speaker:

Lisa Ashworth BS Pharm, BCSCP, FACA

**3:45 pm - 4:45 pm Medical Surveillance for Hazardous Drug Compounding**

ACPE UANs: 0205-9999-26-017-L07-P/T

(0.1 CEU – 1 contact hour)

After this knowledge-based activity, participants will be able to:

1. Outline the key elements and define the organizational partners of a compliant USP<800> Hazardous Drug Medical Surveillance Program.
2. Discuss organizational roles/job functions in the hazardous drug life cycle and identify roles that should be included in a Hazardous Drug Medical Surveillance Program.

# NCBOP Compounding Summit

February 24-26, 2026

Friday Conference Center, Chapel Hill, NC

## CPE Program Details

3. Describe the relationships between hazardous drugs control systems, surface wipe sampling programs, and medical surveillance, and how these elements serve to monitor and minimize exposure risk to hazardous drugs.

Speaker:

Amy Snow, MHS, CIH, CSP, Managing Industrial Hygienist, Safe Bridge

### Thursday, February 26, 2026: Day 2 at Friday Center, Chapel Hill

#### 8:45 am - 10:15 am **Establishing Beyond Use Dates and Testing for Investigations**

ACPE UANs: 0205-9999-26-018-L07-P/T

(0.15 CE – 1.5 contact hours)

After this knowledge-based activity, participants will be able to:

1. Identify the difference between a potency test and a stability-indicating assay by identifying their distinct purposes and analytical outcomes.
2. Explain the characteristics of a stability-indicating analytical method and outline the requirements for establishing and validating such an assay.
3. Describe the regulatory and scientific criteria necessary to design, conduct, and interpret a stability study.
4. Discuss analytical strategies to identify and characterize unknown materials or products, using appropriate instrumental and chemical techniques to determine composition, origin, and potential degradation.

Speaker:

Ross Caputo, PhD, President & CEO, Eagle Analytical

#### 10:30am - 11:30 am **GLP-1 and Peptide Compounding: The Dark Side? Investigative**

##### **Case Studies**

ACPE UANs: 0205-9999-26-019-L07-P/T

(0.1 CEU – 1 contact hour)

After this knowledge-based activity, participants will be able to:

1. Identify recent trends and compounding issues of GLP1 and peptides in prescriber clinics.
2. Identify drug trends and the origin of the drug products, and how to verify these products.
3. Discuss drug testing for investigative purposes.
4. Identify outreach opportunities to educate compounders, providers, and patients.

Speaker: Jenni Wai, RPh, MBA, Chief Pharmacist, Ohio Board of Pharmacy

# **NCBOP Compounding Summit**

**February 24-26, 2026**

**Friday Conference Center, Chapel Hill, NC**

## **CPE Program Details**

**1:00 pm - 2:30 pm** **Creating Effective CAPAs: From Root Cause to Communication Excellence**  
ACPE UANs: 0205-9999-26-020-L07-P/T  
(0.15 CEU- 1.5 Credit Hours)

After this application-based activity, participants will be able to:

1. Describe the essential components of Root Cause Analysis (RCA) and Corrective and Preventive Action (CAPA) and their role in compounding pharmacy quality systems.
2. Apply RCA tools to identify underlying causes of quality deviations in compounding operations.
3. Demonstrate strategies for tailoring CAPA communication to different audiences, including team members, leadership, and regulatory inspectors.
4. Evaluate case study scenarios to develop audience-specific CAPA plans that ensure compliance and prevent recurrence.

Speaker:

Christine Hong, Quality Assurance Manager, Lead Pharmaceutical Microbiologist, AdventHealth

**2:45pm - 3:45pm** **We Put It on Paper on Purpose: Understanding Certification Reports and Data**  
ACPE UANs: 0205-9999-26-021-L07-P/T  
(0.1 CEU – 1 contact hour)

After this knowledge-based activity, participants will be able to:

1. Identify the critical points of certification reports.
2. Recognize the accuracy of raw data in certification reports.
3. Discuss the meaning of certification results as it would correlate to contamination control, risk assessments, and life expectancy of components.

Speaker:

Kyle Mulder, Training and Technical Director, Vanir Technology Group

# **NCBOP Compounding Summit**

## **February 24-26, 2026**

### **Friday Conference Center, Chapel Hill, NC**

### **CPE Program Details**

#### **Virtual Attendance Information**

Zoom Links to connect virtually to the Compounding Summit will be provided to all registered virtual participants via calendar invitation emails the week prior to the Summit.

System requirements: Virtual attendees will need a computer with internet access and audio capabilities. Additional system requirements can be found [here](#).

Privacy Policy <https://www.ncbop.org/privacy-policy.html>

#### **Activity Fees**

Registration: \$295

#### **CPE Information**

The knowledge-based and application-based continuing pharmacy education (CPE) activities presented during the Compounding Summit are designed to meet the educational needs of pharmacists and pharmacy technicians. Participants may earn up to 11 contact hours (1.1 CEU) of Accreditation Council for Pharmacy Education (ACPE)-accredited CPE credit by submitting the activity code(s) at [www.nabp.pharmacy/claimcpe](http://www.nabp.pharmacy/claimcpe). Full attendance, participation, and completion of the online activity and speaker evaluations for each activity and submission of participants' NABP e-Profile ID number and date of birth (MM/DD) are required to receive CPE credit and for the credit to be recorded in the CPE Monitor® system.

If you do not submit your CPE claim within 60 days from the start of the Compounding Summit, you will be unable to receive credit, as this is the maximum amount of time allowed for providers to transmit CPE claims to ACPE. Overrides will not be provided to participants who do not complete all the steps in the claims process within the 60-day window. For questions regarding CPE credit, email [CPE@nabp.pharmacy](mailto:CPE@nabp.pharmacy) for assistance.

Participants are responsible for submitting their own CPE claims; neither the National Association of Boards of Pharmacy® (NABP®) nor the North Carolina Board of Pharmacy will submit CPE credit claims on the participants' behalf.

**Deadline to claim CPE credit: the morning of April 26, 2026**



NABP® and the NABP Foundation® are accredited by ACPE as providers of CPE.  
ACPE Provider Number: 0205.

# **NCBOP Compounding Summit 2026**

## **Speaker Biographies**

**Traci Collier, Pharm D**



**Dr. Collier serves as Director of Regulatory Affairs for Olympia Pharmaceuticals and Wesley Pharmaceuticals, supporting both 503B outsourcing facilities and a 503A compounding pharmacy. She brings extensive regulatory expertise from her tenure as Board Executive and Chief Drug Inspector for the South Carolina Department of Labor, Licensing, and Regulation, specifically for the Board of Pharmacy. Currently, Dr. Collier maintains active involvement in the advancement of the profession through her service on the Board's Compounding Committee and her participation in the South Carolina Pharmacy Association.**

**Currently, Dr. Collier maintains active involvement in advancement of the profession through her service on the Board's Compounding Committee and her participation in the South Carolina Pharmacy Association. Her career foundation was built during 17 years with Kaiser Permanente, where she progressed through diverse pharmacy leadership roles, gaining comprehensive operational and clinical experience.**

**Dr. Collier holds a Doctor of Pharmacy degree from Campbell University College of Pharmacy & Health Sciences.**

# NCBOP Compounding Summit 2026

## Speaker Biographies

**Jessica McAllister**



**Jessica P. McAlister is a seasoned leader in pharmaceutical compliance, with over 14 years of distinguished service at the U.S. Food & Drug Administration (FDA). As the agency's first Pharmacy Compounding National Expert, she played a foundational role in shaping federal oversight of compounding practices and spearheaded the development of the FDA's first outsourcing facility compliance program, which is now a cornerstone of regulatory inspections nationwide. Jessica serves as Senior Director of Compliance at Olympia Pharmaceuticals, where she leads internal audits aligned with the FDA's Outsourcing Facility Compliance Program and 21 CFR Part 210/211.**

**Throughout her FDA tenure, Jessica authored pivotal policies, regulations, and training programs that strengthened the agency's ability to protect public health. Her inspection portfolio spans approximately 250 domestic and international audits across pharmaceutical and compounding sectors, resulting in impactful regulatory actions that prioritized consumer safety.**

**Today, Jessica serves as Senior Director of Compliance at Olympia Pharmaceuticals, where she leads internal audits aligned with FDA's Outsourcing Facility Compliance Program and 21 CFR Part 210/211. She collaborates cross-functionally with Quality, Production, and Engineering teams to drive excellence in process validation, cleaning and disinfectant studies, stability programs, and procedural development. Jessica holds a B.S. in Biology from Rollins College and remains deeply committed to advancing pharmaceutical safety and regulatory integrity.**


# NCBOP Compounding Summit 2026

## Speaker Biographies

**Matt Martin, Pharm D, BCSCP**



**Matt Martin is Vice President of Clinical Services at PCCA. He obtained a degree in chemistry at Morehead State University in 2002 and earned his PharmD from the University of Kentucky College of Pharmacy in 2006. Matt is passionate about quality in all compounding settings and the importance of regulatory compliance and is a frequent speaker at national conferences on quality and compliance. He has served on several boards of pharmacy committees, as well as on the board of directors for local, state, and national pharmacy organizations. Currently, Matt serves as the Chair of APhA's Compounding Community.**



# **NCBOP Compounding Summit 2026**

## **Speaker Biographies**

**Michel van Musschenbroek**



**Michel van Musschenbroek is a North American Field Marketing and Applications Manager supporting the Pharmaceutical Industry and has worked for MilliporeSigma over 35 years.**

**During that time, he has supported customers in a variety of positions, from Technical Service, Inside and Field sales for Pharmaceutical and Compounding markets, focusing on in-process and sterility testing. In October of 2019 he started a new position as part of the Field Marketing and Applications Team.**

**Outside of work he is a nationally certified coach and coach trainer working with local Middle and High School students in the sport of mountain biking in the state of Georgia**

# NCBOP Compounding Summit 2026

## Speaker Biographies

Lisa Diggs Ashworth, BS Pharm, RPh, BCSCP, FACA



Lisa Diggs Ashworth is a pharmacy compounding consultant and leader with over 45 years of experience spanning retail, hospital, home infusion, investigational studies, drug information services as contributing editor and writer for the *International Journal of Pharmaceutical Compounding (IJPC)*, and as a preceptor for students and residents. Lisa is co-author of *Trissel's Stability of Compounded Formulations*, 6th ed. and a contributor to *Remington: The Science and Practice of Pharmacy*, 22nd ed. Board Certified in Sterile Compounding, she has served on the USP Compounding Expert Committee since 2005, contributing to the development of global standards that she has spoken about around the world. Lisa specializes in sterile, nonsterile, and hazardous drug compounding, offering expertise in regulatory compliance, SOPs, and best practices. She especially has a passion for pediatric formulations and expanding access to safe, effective compounded therapies. She earned a BS in Pharmacy from the University of Oklahoma College of Pharmacy.

# NCBOP Compounding Summit 2026

## Speaker Biographies

**Amy Snow, MHS, CIH, CSP**



**Amy is the Senior Managing Industrial Hygienist at SafeBridge Consultants, Inc. She has over 25 years of diverse experience in industrial hygiene, safety, risk assessment, and EHS program implementation. She has served in several roles throughout her career in the pharma industry, including manufacturing and R&D, university EHS, and OSHA regulatory and consultation management. Amy has been an AIHA and ACGIH volunteer and leader throughout her career. She served as the lead author for the cross-disciplinary volunteer team that published the AIHA Hazardous Drug Surface Contamination Guidance Document. Amy was recently elected as a director-at-large for the AIHA Board of Directors.**

# NCBOP Compounding Summit 2026

## Speaker Biographies

**Ross Caputo, PhD**



**Ross Caputo, PhD, received his Bachelor of Science in Biological Science in 1971 from the Ohio State University, his Master's in Molecular Genetics in 1974, and his PhD in Microbiological Physiology and Immunology from Miami University in 1976. He has over 35 years of experience in the FDA-regulated pharmaceutical industry on sterilization research and aseptic processing focusing on process optimization and control. Dr. Caputo has authored more than 50 publications and is credited with 12 US patents and many international patents – all related to infection control, sterilization processes and the production of sterile product. Throughout his career Dr. Caputo has been an active participant in and a committee member in organizations, such as AAMI/ISO and PDA, charged with the development of standards for the regulated marketplace.**

# NCBOP Compounding Summit 2026

## Speaker Biographies

**Jenni Wai RPh, MBA**



**Jenni Wai is Chief Pharmacist at the Ohio Board of Pharmacy, where she plays a pivotal role in ensuring the safety, integrity, and accessibility of drugs and pharmacy care across the state. With a career dedicated to upholding the highest standards of pharmacy practice and healthcare, Jenni is a trusted authority in regulatory and compliance matters, bringing over 25 years of experience and expertise. In her role as Chief Pharmacist at the Ohio Board of Pharmacy, Jenni leads a team of dedicated professionals responsible for overseeing pharmacy licensure, compliance, and enforcement activities. With a keen understanding of state and federal regulations governing pharmacy practice and drug distribution, she works to safeguard public health and promote best practices within the profession.**

# NCBOP Compounding Summit 2026

## Speaker Biographies

**Christine Hong, ASQ-Certified Pharmaceutical GMP Professional**



**Christine Hong is a recognized subject matter expert in pharmaceutical microbiology and quality systems, currently serving as Lead Pharmaceutical Microbiologist and Quality Assurance Manager for AdventHealth's Pharmacy Microbiological Quality Services (PMQS) program. She leads a centralized Environmental Monitoring program supporting over 40 facilities, overseeing all aspects from sample collection to incubation, analysis, and quality investigations for sterile compounding environments. With extensive experience in pharmaceutical manufacturing, medical devices, and 503B outsourcing, Christine brings deep expertise in aseptic processing, CAPA management, compliance auditing, microbiological and stability testing, and root cause analysis. She has successfully guided organizations through complex regulatory challenges and quality system enhancements.**

**Christine will present on creating effective CAPAs from root cause to communication. She will describe the essential components of Root Cause Analysis (RCA) and Corrective and Preventive Action (CAPA) and their role in compounding pharmacy quality systems. Apply RCA tools to identify underlying causes of quality deviations in compounding operations. She will demonstrate strategies for tailoring CAPA communication to different audiences, including team members, leadership, and regulatory inspectors. Additionally, she will evaluate case study scenarios to develop audience-specific CAPA plans that ensure and prevent recurrence.**

# NCBOP Compounding Summit 2026

## Speaker Biographies

**Kyle Mulder**



As Training and Technical Director at VTG LLC, Kyle Mulder is responsible not only for staying up to date with current industry requirements and trends but also for incorporating changes into internal processes and disseminating information throughout the company worldwide. Kyle served on NSF/ANSI 49 Joint committee, CAG 009, CAG 002 and CAG 003 review committees, CAG 011, 013, and 014 creation committees, secretary for IEST-RP-CC050 Design and Construction considerations for USP <800> compliant suites, teaching courses through IEST on cleanroom compliance aspects, NEBB cleanroom performance testing (CPT) committee in addition to publishing several articles with the International Journal of Pharmaceutical Compounding. With 21 years of varied experience in contamination control, NSF accreditation, CETA SCF accreditation, and NEBB CPT CP accreditation, supplemented by numerous training courses, Kyle has the tools to continually push the boundaries of quality, technique, and compliance within our industry.

Kyle will present Cleanroom Certification and what the data means. He will navigate critical points of the certification report and assess the accuracy of the raw data in certification reports. He will also discuss the meaning of certification results as it would correlate to contamination control, risk assessments, and the life expectancy of components